Microglial state transitions are constrained by developmental and metabolic checkpoints

Single-cell transcriptomic and epigenomic profiling has revealed extensive microglial heterogeneity across development, homeostasis, and disease. However, one recurring observation remains unexplained. Only subsets of microglia adopt expected transcriptional programs in a given context, and transcriptional activation often fails to translate into functional execution. Current frameworks describe microglial states, but they do not explain why individual cells differ in their ability to access, sustain, or complete state transitions. Here, we propose a checkpoint framework for microglial state transitions. In this model, transitions depend on prerequisite conditions that must be met before a response can proceed. We use the term checkpoint in the sense of cell-cycle biology, where progression depends on prior conditions, rather than in the signal-integration sense used for peripheral immune checkpoints. We first consider the peripheral checkpoint model, in which transitions are driven mainly by activating and inhibitory receptor signaling. In that system, continuous hematopoietic renewal buffers many individual cell-level constraints. We then argue that this logic is modified in microglia. Their embryonic origin, lifelong residence in the CNS, and limited replacement capacity make cellular history a more durable determinant of responsiveness. Within this framework, we define three non-redundant classes of checkpoint-like constraints. The first is developmental licensing, which establishes accessible response space through lineage specification, postnatal maturation, and age-dependent stabilization. The second is metabolic and proteostatic capacity, which determines whether cells can meet the energetic and protein-handling demands required for execution. The third is tissue-derived gating, in which neuronal, astrocytic, and extracellular matrix signals set permissive or non-permissive conditions for transition. Together, these constraints help explain why microglial responses are heterogeneous, why transcriptional state and functional output can diverge, and why disease-associated profiles may reflect stalled or incomplete transitions rather than stable functional identities. This framework shifts attention from descriptive states to constrained transitions. It also suggests that therapy should focus on restoring transition competence rather than simply suppressing or inducing specific microglial states.